COVID-19 infection-associated coagulopathy and its association with adverse outcomes in Indian gravidas: a prospective analysis

Soumya P. Singh; Preeti Singh; Rohini Gaonkar

doi:10.18203/2320-1770.ijrcog20233637

Authors

Soumya P. Singh Department of Obstetrics and Gynecology, Maulana Azad Medical College, New Delhi, Delhi, India
Preeti Singh Department of Obstetrics and Gynecology, Maulana Azad Medical College, New Delhi, Delhi, India
Rohini Gaonkar Department of Obstetrics and Gynecology, Maulana Azad Medical College, New Delhi, Delhi, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20233637

Keywords:

COVID-19, Pregnancy, Coagulopathy, D-dimer

Abstract

Background: Objective of the study was the determination of trends of coagulation parameters and association between pregnant women with COVID-19 infection with adverse outcomes.

Methods: Design of the study was a prospective observational study. The study was conducted at the Maulana Azad Medical College and associated Lok Nayak Hospital, New Delhi. A total of 142 pregnant women with confirmed COVID-19 infection were recruited and studied prospectively between May 2020 and April 2021. Trends of coagulation parameters were compared in groups divided based on the adverse outcomes. 11 patients had adverse outcomes which included ICU admission or mortality. There were no adverse outcomes in the remaining 131 patients.

Results: The comparison of trends of coagulation parameters in both groups was studied. D-dimer and INR values were significantly higher, while fibrinogen level was significantly lower in COVID-19 subjects with adverse maternal outcomes than in those in which adverse maternal outcomes were not present (p<0.05). No significant difference was observed in other coagulation parameters like APTT.

Conclusions: Universal screening of coagulation parameters of all pregnant women with COVID-19 can be considered because of the association of adverse maternal outcomes with deranged D dimer and fibrinogen in our study.

Metrics

Metrics Loading ...

References

Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-81.

Johns Hopkins University. Johns Hopkins University Coronavirus Resource Center. Available at: https://coronavirus.jhu.edu/map.html. Accessed on 23 April 2020.

Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003;361(9366):1319-25.

Kupferschmidt K. Researchers scramble to understand camel connection to MERS[J]. Science. 2013;341(6147):702.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019[J]. N Engl J Med. 2020;382(8):727-33.

Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol. 2020;127:104362.

Subramaniam S, Scharrer I. Procoagulant activity during viral infections. Front Biosci (Landmark Ed). 2018;23:1060-81.

Van Gorp EC, Suharti C, Ten Cate H, Dolmans WM, van der Meer JW, Ten Cate JW, et al. Infectious diseases and coagulation disorders. J Infect Dis. 1999;180(1):176-86.

Key NS, Vercellotti GM, Winkelmann JC, Moldow CF, Goodman JL, Esmon NL, et al. Infection of vascular endothelial cells with herpes simplex virus enhances tissue factor activity and reduces thrombomodulin expression. Proc Natl Acad Sci. 1990;87:7095-9.

Wang ZF, Su F, Lin XJ, Dai B, Kong LF, Zhao HW, et al. Serum D-dimer changes and prognostic implication in 2009 novel influenza A(H1N1). Thromb Res. 2011;127(3):198-201.

Vlachodimitropoulou Koumoutsea E, Vivanti AJ, Shehata N, Benachi A, Le Gouez A, Desconclois C, et al. COVID-19 and acute coagulopathy in pregnancy. J Thromb Haemost. 2020;18(7):1648-52.

Servante J, Swallow G, Thornton JG, Myers B, Munireddy S, Malinowski AK, et al. Haemostatic and thrombo-embolic complications in pregnant women with COVID-19: a systematic review and critical analysis. BMC Pregnancy Childbirth. 2021;21(1):108.

Rostami M, Mansouritorghabeh H. D-dimer level in COVID-19 infection: a systematic review. Expert Rev Hematol. 2020;13(11):1265-75.

Long H, Nie L, Xiang X, Li H, Zhang X, Fu X, et al. D-Dimer and prothrombin time are the significant ındicators of severe COVID-19 and poor prognosis. Biomed Res Int. 2020;6159720.

Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033-40.

Di Renzo GC, Giardina I. Coronavirus disease 2019 in pregnancy: consider thromboembolic disorders and thromboprophylaxis. Am J Obstet Gynecol. 2020;223(1):135.

Cuker A, Tseng EK, Nieuwlaat R, Angchaisuksiri P, Blair C, Dane K, et al. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Adv. 2021;5(3):872-88.

Pereira A, Cruz-Melguizo S, Adrien M, Fuentes L, Marin E, Perez-Medina T. Clinical course of coronavirus disease-2019 in pregnancy. Acta Obstet Gynecol Scand. 2020;99(7):839-47.

Shmakov RG, Prikhodko A, Polushkina E, Shmakova E, Pyregov A, Bychenko V, et al. Clinical course of novel COVID-19 infection in pregnant women. J Matern Fetal Neonatal Med. 2020;35(23):4431-7.

Hazari KS, Abdeldayem R, Paulose L, Kurien N, Almahloul Z, Mohammad H, et al. Covid-19 infection in pregnant women in dubai: a case-control study. BMC Pregnancy Childbirth. 2021;21(1):658.